Lead Sponsor

AstraZeneca

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Clinical indication for coronary catheterization. Target Coronary Artery: The target vessel must have .50% reduction in lumen diameter by angiographic visual estimation throughout a segment of at least 40 mm in length (the target segment) and the vessel must be large enough to accommodate the IVUS catheter. A lesion of up to 60% is permitted distal to the target segment. Side branches of the target (imaged) vessel may be narrowed up to 70% by visual estimation, provided the target segment contains no lesion greater than 50%.

•Use of lipid-lowering medication for more than 3 months within the previous 12 months. Longer periods of treatment are not permitted because of the potential effects of such therapy on coronary atherosclerosis. Subjects receiving treatment with a lipid-lowering medication within the past 4 weeks require a 4-week wash-out period following which a baseline lipid profile will be taken at visit 2.
•Clinically significant heart disease which, in the opinion of the Principal Investigator (or designee), is likely to require coronary bypass surgery, cardiac transplantation, surgical repair and/or replacement during the course of the study.
•\-

Related studies

NCT06701968 · Coronary Disease, Coronary Arteriosclerosis, and more

NCT06794684 · Coronary Arterial Disease (CAD), Coronary Arteriosclerosis

NCT06075602 · Coronary Disease, Coronary Artery Disease, and more

NCT04827316 · Coronary Artery Disease, Coronary Arteriosclerosis, and more

NCT06577038 · Calcific Coronary Arteriosclerosis

A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)